Literature DB >> 3754453

The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.

I J Stratford, J M Walling, A R Silver.   

Abstract

The hypoxic cell radiosensitizer RSU 1069 (1-(2-nitro-1-imidazolyl)-3-(1-aziridinyl)-2-propanol) shows, on a concentration basis, a 100-fold greater toxicity towards hypoxic relative to aerobic cells. This toxicity is substantially greater than that of misonidazole, a compound of similar electron affinity. Reductive processes are important for hypoxic toxicity; this is demonstrated by the fact that misonidazole, in excess, can protect against the hypoxic but not aerobic toxicity of RSU 1069. The importance of the interaction of RSU 1069 with DNA, suggested initially by molecular studies, is supported by the fact that cells containing 5-bromodeoxyuridine (5-BUdR) incorporated into their DNA show greater sensitivity towards the lethal effects of RSU 1069 both in air and nitrogen, compared to cells not treated with 5-BUdR. Experiments with RSU 1069 and 3-aminobenzamide (3-AB) show the latter compound to potentiate aerobic toxicity, consistent with monofunctional alkylation by RSU 1069. In contrast, 3-AB has no effect on the hypoxic cytotoxicity of RSU 1069, which would be predicted if RSU 1069 is functioning as a bifunctional agent under these conditions. It is our contention that in air, RSU 1069 functions as a typical monofunctional alkylating agent, presumably due to the presence of the aziridine group whereas, in hypoxia, reduction of the nitro group provides an additional alkylating species, converting the compound into a bifunctional agent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754453      PMCID: PMC2001359          DOI: 10.1038/bjc.1986.57

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Pyridine nucleotide levels as a function of growth in normal and transformed 3T3 cells.

Authors:  E L Jacobson; M K Jacobson
Journal:  Arch Biochem Biophys       Date:  1976-08       Impact factor: 4.013

2.  The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea.

Authors:  C J Skidmore; M I Davies; P M Goodwin; H Halldorsson; P J Lewis; S Shall; A A Zia'ee
Journal:  Eur J Biochem       Date:  1979-11-01

3.  Regulation of DNA ligase activity by poly(ADP-ribose).

Authors:  D Creissen; S Shall
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

4.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

Authors:  O W Griffith
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

5.  Increased sensitivity of mammalian cell cultures to radiomimetic alkylating agents following incorporation of 5-bromodeoxyuridine into cellular DNA.

Authors:  R Schindler; L Ramseier; A Grieder
Journal:  Biochem Pharmacol       Date:  1966-12       Impact factor: 5.858

6.  Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.

Authors:  G E Adams; I R Flockhart; C E Smithen; I J Stratford; P Wardman; M E Watts
Journal:  Radiat Res       Date:  1976-07       Impact factor: 2.841

7.  The enhancement of cytotoxicity of N-methyl-N-nitrosourea and of gamma-radiation by inhibitors of poly(ADP-ribose) polymerase.

Authors:  N Nduka; C J Skidmore; S Shall
Journal:  Eur J Biochem       Date:  1980-04

8.  Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.

Authors:  I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

9.  Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential.

Authors:  G E Adams; I J Stratford; R G Wallace; P Wardman; M E Watts
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

10.  Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity.

Authors:  B DJORDJEVIC; W SZYBALSKI
Journal:  J Exp Med       Date:  1960-09-01       Impact factor: 14.307

View more
  9 in total

1.  High uptake of RSU 1069 and its analogues melanotic melanomas.

Authors:  J M Walling; J Deacon; S Holliday; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

Authors:  S J Lunt; C Cawthorne; M Ali; B A Telfer; M Babur; A Smigova; P J Julyan; P M Price; I J Stratford; W D Bloomer; M V Papadopoulou; K J Williams
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

3.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

Authors:  K H Wong; C J Koch; C A Wallen; K T Wheeler
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

5.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

Authors:  L M Cobb; J Nolan; S A Butler
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

6.  Bioreductive drugs and the selective induction of tumour hypoxia.

Authors:  J C Bremner; I J Stratford; J Bowler; G E Adams
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

7.  Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

Authors:  D J Chaplin
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

8.  Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.

Authors:  P L Olive
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.

Authors:  I J Stratford; G E Adams; J Godden; J Nolan; N Howells; N Timpson
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.